Replies to post #788090 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

e❌,

Thanks for reposting your x-ceptional insights 😶

Luckily, Dr. Liau is there to sort out any discrepancies, so you don’t have to be concerned anymore:




⭐️ AACR Advances in Ovarian Cancer Research

⭐️ NWBO to Acquire Advent BioServices

⭐️ Recent Conference

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

⭐️ 10-Q Quarterly Report

⭐️ 10-K Annual Report

⭐️ NICE UK 🇬🇧 DCVax-L

⭐️ ASM June 29, 2024

⭐️ Manufacturing Technology

⭐️ NWBO Acquires Flaskworks

⭐️ Roswell Park IP Portfolio

⭐️ TLR3 agonist Ampligen (rintatolimod)

⭐️ Next Generation Dendritic Cell Treatments





⭐️Combo is King!⭐️

AI Fact-Checking

[biosectinvestor]

ATL-DC is DCVax-L — the record is conclusive, and local manufacturing does NOT make it not murcidencel.

First, we have previous discussion: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173662761

But more specifically to your points...

The comparison to Opdivo and Keytruda is completely false. Opdivo (nivolumab) and Keytruda (pembrolizumab) are distinct monoclonal antibodies with different amino acid sequences, different binding sites, and different corporate sponsors. By contrast, ATL-DC and DCVax-L are the same autologous tumor lysate–pulsed dendritic cell vaccine — described under different labels depending on context.

The authoritative record:

• UCLA Health (Sept 2024 press release): UCLA explicitly identifies the vaccine pioneered by Dr. Liau in 1997, advanced through Phase 1/2/3, and published in JAMA Oncology, as DCVax-L.
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers

• Phase 3 trial (JAMA Oncology, 2022): The pivotal paper is titled:
“Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival…” and explicitly names the product DCVax-L.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

• NCI/UCLA SPORE grant: NIH documents describe the same lysate-pulsed DC vaccine as DCVax-L, even when UCLA used the shorthand “ATL-DC” in unsponsored trials.
https://trp.cancer.gov/spores/abstracts/ucla_brain.htm#h03

• WHO INN: The vaccine has been assigned the INN murcidencel, the official global name for autologous dendritic cells pulsed with autologous tumor lysate.

• Czech pediatric trial: A Phase I/II study at Masaryk University for children and adolescents with high-risk tumors is registered as using murcidencel, even though the product is prepared locally and given fresh — exactly like UCLA’s ATL-DC. This shows regulators recognize murcidencel regardless of whether doses are fresh or cryopreserved, because the underlying therapy is the same.

https://clinicaltrials.eu/trial/study-on-murcidencel-for-children-adolescents-and-young-adults-with-high-risk-progressive-or-recurrent-metastatic-tumors

The only distinction is contextual:
• “ATL-DC” = academic shorthand used at UCLA.
• “DCVax-L” = sponsor’s brand for registrational development.
• “Murcidencel” = WHO’s international name.

Same recipe, same therapy, same product. Logistics (fresh vs. cryopreserved, local vs. centralized) don’t make it a different drug.

That is a superficial distinction. The regulators are clearly already comfortable with that conclusion given the above.

Bottom line: Every definitive source — UCLA, JAMA Oncology, NIH, WHO, and now a Czech trial — confirms the same truth: ATL-DC is DCVax-L, now formally murcidencel. Claims to the contrary are smoke meant to create doubt where none exists.